Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
作者信息
Ma Z, Sun X M, Lu W C, Zhao Z X, Xu Z M, Lyu J Y, Zhao P, Liu L H
机构信息
Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
出版信息
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
Abstract
摘要
相似文献
1
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.聚（ADP - 核糖）聚合酶抑制剂相关的骨髓增生异常综合征/急性髓系白血病：FAERS数据库的药物警戒分析
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
2
Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.急性髓系白血病作为聚（ADP-核糖）聚合酶（PARP）抑制剂治疗患者的不良事件。
Am J Hematol. 2023 Oct;98(10):1665-1666. doi: 10.1002/ajh.26969. Epub 2023 May 25.
3
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.接受 PARP 抑制剂治疗的患者的骨髓增生异常综合征和急性髓系白血病：随机对照试验的安全性荟萃分析和世界卫生组织药物警戒数据库的回顾性研究。
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
4
Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.接受聚ADP核糖聚合酶抑制剂治疗的卵巢癌女性患者的继发性血液系统恶性肿瘤
Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
5
Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.接受聚（ADP - 核糖）聚合酶（PARP）抑制剂治疗的癌症患者中的髓系恶性肿瘤：病例系列
Blood Cancer J. 2022 Jan 25;12(1):11. doi: 10.1038/s41408-022-00607-7.
6
PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.PARP抑制剂——了解骨髓增生异常综合征和急性髓系白血病的风险
Lancet Haematol. 2021 Feb;8(2):e97-e99. doi: 10.1016/S2352-3026(20)30375-6. Epub 2020 Dec 18.
7
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.实体瘤患者接受聚（ADP - 核糖）聚合酶蛋白抑制剂治疗后发生治疗相关髓系肿瘤的患者结局。
Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23.
8
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.抑制聚（ADP-核糖）聚合酶1通过抑制骨髓增殖性白血病病毒癌基因来预防急性髓系白血病。
Oncotarget. 2015 Sep 29;6(29):27490-504. doi: 10.18632/oncotarget.4748.
9
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.聚 ADP - 核糖聚合酶（PARP）抑制剂可诱导髓系白血病细胞凋亡：对髓系白血病和骨髓增生异常综合征的治疗潜力。
Haematologica. 2009 May;94(5):638-46. doi: 10.3324/haematol.2008.001933.
10
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.聚（ADP - 核糖）聚合酶抑制剂相关的髓系肿瘤：来自法国药物警戒中心网络的一项回顾性研究
Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5.
引用本文的文献
1
Chromatin organization in myelodysplastic syndrome.骨髓增生异常综合征中的染色质组织。
Exp Hematol. 2024 Jun;134:104216. doi: 10.1016/j.exphem.2024.104216. Epub 2024 Apr 4.
2
Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice.Foxm1 杂合性不足导致小鼠克隆性造血，并促进与应激相关的向血液系统恶性肿瘤的转变。
J Clin Invest. 2023 Aug 1;133(15):e163911. doi: 10.1172/JCI163911.
3
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.辅助奥拉帕利治疗 HER2 阴性早期乳腺癌的胚系 BRCA 携带者：证据与争议。
Oncologist. 2023 Jul 5;28(7):565-574. doi: 10.1093/oncolo/oyad123.
4
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.癌症治疗与耐药中的 DNA 损伤反应：挑战与机遇。
Int J Mol Sci. 2022 Nov 24;23(23):14672. doi: 10.3390/ijms232314672.
5
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.使用聚腺苷二磷酸核糖聚合酶（PARP）抑制剂后发生的骨髓增生异常综合征/急性髓系白血病：上市后监测数据的真实世界分析
Front Pharmacol. 2022 Jun 15;13:912256. doi: 10.3389/fphar.2022.912256. eCollection 2022.
6
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.一切皆有代价：DNA损伤反应靶向药物的毒性概况。
Cancers (Basel). 2022 Feb 14;14(4):953. doi: 10.3390/cancers14040953.
Zotero 插件